A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate whether anemia prevention with NeoRecormon has an additional impact
on reducing cardiovascular risk over conventional anemia treatment in patients mostly with
stage IV chronic kidney disease and renal anemia. The anticipated time on study treatment is
2+ years and the target sample size is 500+ individuals.